FluBHPVE6E7

BIOLOGICAL3 trials

Sponsors

BlueSky Immunotherapies GmbH

Conditions

HPV InfectionHPV-Related Cervical CarcinomaOropharyngeal Squamous Cell Carcinoma (SCC)

Phase 1

Study of FluBHPVE6E7 in HPV-16 Infected Women

CompletedNCT04490512

BlueSky Immunotherapies GmbHHPV Infection

Start: 2020-12-09End: 2023-06-06Updated: 2023-06-26

Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women

RecruitingNCT05829629

BlueSky Immunotherapies GmbHHPV Infection, HPV-Related Cervical Carcinoma

Start: 2023-09-12End: 2025-11-30Target: 20Updated: 2025-02-14

Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer

RecruitingNCT06589609

BlueSky Immunotherapies GmbHOropharyngeal Squamous Cell Carcinoma (SCC)

Start: 2024-08-23End: 2029-11-30Target: 12Updated: 2024-09-19